MiRaDor Trial marks first-ever joint effort by MEDSIR and Oncoclinicas & Co in pioneering breast cancer research: The MiRaDor trial, a proof-of-concept study, aims to evaluate the usefulness of ctDNA analysis to detect Minimal Residual Disease in early breast cancer patients who are at high risk of relapse This marks the first-time MEDSIR and Oncoclínicas will join forces to perform a trial together,...
